Hepatitis B: New Therapies for HBV and HDV
Nov
12
2023
Room 304/306
-
Hynes Convention Center
8:30
- 10:00 AM EST
Speakers
Description
Abstracts
- A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND TREATMENT REGIMENS OF VTP-300 COMBINED WITH LOW-DOSE NIVOLUMAB IN CHRONIC HEPATITIS B INFECTION
- PEGYLATED INTERFERON REDUCES RELAPSES FOLLOWING BEPIROVIRSEN TREATMENT IN PARTICIPANTS WITH CHRONIC HEPATITIS B VIRUS INFECTION ON NUCLEOS(T)IDE ANALOGUES: END OF STUDY RESULTS FROM THE PHASE 2b B-TOGETHER STUDY
- PERIPHERAL SINGLE CELL GENE EXPRESSION CHANGES IN RESPONSE TO TOLL-LIKE RECEPTOR 8 AGONIST TREATMENT IN CHRONIC HEPATITIS B PATIENTS
- LONG TERM HBsAg REDUCTION BY A NASAL ADMINISTRATIVE THERAPEUTIC VACCINE CONTAINING HBsAg AND HBCAG MIXED WITH MUCOADHESIVE CVP IN PATIENTS WITH CHRONIC HBV INFECTION: THE RESULTS OF 48 MONTHS FOLLOW UP
- PRELIMINARY OFF-TREATMENT RESPONSES FOLLOWING 48 WEEKS OF VEBICORVIR, NUCLEOS(T)IDE REVERSE TRANSCRIPTASE INHIBITOR, AND AB-729 COMBINATION IN VIROLOGICALLY SUPPRESSED PATIENTS WITH HEPATITIS B E ANTIGEN NEGATIVE CHRONIC HEPATITIS B: ANALYSIS FROM AN OPEN-LABEL PHASE 2 STUDY
- INTRAHEPATIC CHANGES IN VIRAL AND IMMUNE MARKERS FOLLOWING TREATMENT WITH JNJ-73763989 (JNJ-3989) AND NUCLEOS(T)IDE ANALOGS (NAS), IN PATIENTS WITH CHRONIC HEPATITIS B (CHB): INSIGHT WEEK 40 (W40) INTERIM RESULTS